4//SEC Filing
Haag-Molkenteller Cornelia 4
Accession 0000899243-21-014109
CIK 0001740547other
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 12:30 PM ET
Size
14.8 KB
Accession
0000899243-21-014109
Insider Transaction Report
Form 4
Haag-Molkenteller Cornelia
CMO of Urovant Sciences, Inc.
Transactions
- Disposition to Issuer
Common Shares
2021-03-29−129,745→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-29−1,000→ 0 totalExercise: $13.65Exp: 2028-10-14→ Common Shares (1,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-29−100,000→ 0 totalExercise: $6.88Exp: 2029-01-06→ Common Shares (100,000 underlying) - Disposition to Issuer
Common Shares
2021-03-29−11,603→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-29−146,850→ 0 totalExercise: $7.53Exp: 2028-05-20→ Common Shares (146,850 underlying)
Footnotes (3)
- [F1]Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
- [F2]Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
- [F3]Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Documents
Issuer
Urovant Sciences Ltd.
CIK 0001740547
Entity typeother
Related Parties
1- filerCIK 0001748297
Filing Metadata
- Form type
- 4
- Filed
- Mar 30, 8:00 PM ET
- Accepted
- Mar 31, 12:30 PM ET
- Size
- 14.8 KB